Frank E. Thomas

CIK: 0001242616

Transaction Breakdown

Open Market Buys (P)1 (20.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

SPRO

Spero Therapeutics, Inc.

Director

LRMR

Larimar Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

SPRO
Spero Therapeutics, Inc.
Jun 23, 2026
Award(A)
Direct
10K shares-
LRMR
Larimar Therapeutics, Inc.
May 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
55.2K shares-
LRMR
Larimar Therapeutics, Inc.
Feb 27, 2026
Purchase(P)
Direct
5K shares at avg. $5.00$25K
SPRO
Spero Therapeutics, Inc.
Jun 12, 2025
Award(A)
Direct
20K shares-
LRMR
Larimar Therapeutics, Inc.
May 13, 2025
Award(A)
Stock Option (Right to Buy)
Direct
19K shares-

		Type	Shares	Price		Ownership
Jun 23, 2026	SPRO Spero Therapeutics, Inc.	Award(A)	10,000	-	$0	Direct
May 19, 2026	LRMR Larimar Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	55,150	-	-	Direct
Feb 27, 2026	LRMR Larimar Therapeutics, Inc.	Purchase(P)	5,000	$5.00	$25,000	Direct
Jun 12, 2025	SPRO Spero Therapeutics, Inc.	Award(A)	20,000	-	-	Direct
May 13, 2025	LRMR Larimar Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	19,000	-	-	Direct

1-5 of 5 transactions

About THOMAS FRANK E

THOMAS FRANK E (SEC CIK 0001242616) files insider reports with the SEC as Director of Spero Therapeutics, Inc. (SPRO) and Director of Larimar Therapeutics, Inc. (LRMR).

Signal8 holds 5 ownership filings by THOMAS FRANK E, all Form 4s, filed between May 14, 2025 and Jun 25, 2026. Those filings report 5 transactions, from May 13, 2025 to Jun 23, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on THOMAS FRANK E's filings is in CAMBRIDGE, MA.

Recent filings by THOMAS FRANK E

Jun 23, 2026: Grant or award of SPRO shares (Form 4, code A).
May 19, 2026: Grant or award of LRMR derivative securities (Form 4, code A).
Feb 27, 2026: Open-market purchase of LRMR shares (Form 4, code P).
Jun 12, 2025: Grant or award of SPRO shares (Form 4, code A).
May 13, 2025: Grant or award of LRMR derivative securities (Form 4, code A).

Other insiders filing for Spero Therapeutics, Inc. (SPRO)

Zack Debra, Chief Medical Officer
Deshpande Milind, Director
Tregoning Kathleen, Director
Smith Cynthia, Director
VINK PATRICK V.J.J., Director
Jackson Scott Thomas, Director

How to read Form 4 transaction codes